Skip to main content Accessibility help
Hostname: page-component-797576ffbb-cx6qr Total loading time: 0 Render date: 2023-12-06T18:05:13.863Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "useRatesEcommerce": true } hasContentIssue false

Chapter Forty Seven - Aspirin

from Treatment

Published online by Cambridge University Press:  13 December 2022

Louis R. Caplan
Beth Israel Deaconess Medical Centre
Aishwarya Aggarwal
John F. Kennedy Medical Center
Get access


Ancient medical practitioners believed in the “doctrine of signatures,” which stated that natural objects that resembled parts of the body could cure diseases affecting those parts. The eyebright plant was used to cure eye diseases due to the similitude of its flowers to blue eyes. The famous Swiss physician Paracelsus was a proponent of this doctrine and stated, “Nature marks each growth, according to its curative benefit.” Herbs were believed to have particular “signatures” given by God for people to identify and use. Although this doctrine had no scientific basis, it led to the discovery of a drug widely used today [1].

Stories of Stroke
Key Individuals and the Evolution of Ideas
, pp. 447 - 454
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Notes and References

Stone, E. XXXII. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edward Stone, of Chipping-Norton in Oxfordshire. Philos. Trans. 1763 Jan 1;53:195200.Google Scholar
Jack, DB. One hundred years of aspirin. Lancet Lond. Engl. 1997 Aug 9;350(9075):437439.CrossRefGoogle ScholarPubMed
Pearce, JMS. The controversial story of aspirin. World Neurology. December 2, 2014. Available at Scholar
Buchanan, WW, Kean, WF. The treatment of acute rheumatism by salicin, by T. J. Maclagan – The Lancet, 1876. J. Rheumatol. 2002 Jun 1;29(6):13211323.Google Scholar
Snead, MW, Aikawa, JK. T. J. Maclagan and the treatment of rheumatic fever with salicin. AMA Arch. Intern. Med. 1958 May 1;101(5):9971004.CrossRefGoogle Scholar
Malverde, J. How aspirin turned hero: Heroin, Bayer and Heinrich Dreser. Democratic Underground. Available at Scholar
Lichterman, BL. Aspirin: The story of a wonder drug. BMJ 2004 Dec 11;329(7479):1408.CrossRefGoogle Scholar
Miner, J, Hoffhines, A. The discovery of aspirin’s antithrombotic effects. Tex. Heart Inst. J. 2007;34(2):179186.Google ScholarPubMed
Craven, LL. Coronary thrombosis can be prevented. J. Insurance Med. 1950;5:4748.Google ScholarPubMed
Craven, LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss. Valley Med. J. 1953;75:3844.Google ScholarPubMed
Craven, LL. Prevention of coronary and cerebral thrombosis. Miss. Valley Med. J. 1956;78:213215.Google ScholarPubMed
Weiss, HJ, Aledort, LM, Kochwa, S. The effect of salicylates on the hemostatic properties of platelets in man. J. Clin. Invest. 1968;47:21692180.CrossRefGoogle ScholarPubMed
Vane, JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971;231:232235.CrossRefGoogle ScholarPubMed
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349360.Google Scholar
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:7186.CrossRefGoogle Scholar
Bell, AD, Roussin, A, Cartier, R, Chan, WS, Douketis, JD, Gupta, A, Kraw, ME, Lindsay, TF, Love, MP, Pannu, N, Rabasa-Lhoret, R, Shuaib, A, Teal, P, Théroux, P, Turpie, AG, Welsh, RC, Tanguay, JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can. J. Cardiol. 2011;27:208221.CrossRefGoogle Scholar
Graham, I, Atar, D, Borch-Johnson, K, et al. for the ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007;194:145.CrossRefGoogle ScholarPubMed
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2009;150:396404.CrossRefGoogle Scholar
Vandvik, PO, Lincoff, AM, Core, JM, et al. for American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e637Se668S.CrossRefGoogle ScholarPubMed
Mundall, J, Quintero, P, von Kaulla, K, et al. Transient monocular blindness and increased platelet aggregability treated with aspirin: A case report. Neurology 1971;21:402.Google Scholar
Harrison, MJG, Marshall, J, Meadows, JC, et al. Effect of aspirin in amaurosis fugax. Lancet 1971;2:743744.CrossRefGoogle ScholarPubMed
Fields, WS, Lemak, N, Frankowski, R, Hardy, RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301306.CrossRefGoogle ScholarPubMed
Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 1978;299:5359.CrossRefGoogle Scholar
UK-TIA Study Group. The UK-TIA Aspirin Trial: The interim results. BMJ 1988;296:316320.CrossRefGoogle Scholar
The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:13451349.CrossRefGoogle Scholar
The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor stroke. N. Engl. J. Med. 1991;325:12611266.CrossRefGoogle Scholar
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81106.CrossRefGoogle Scholar
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;524:7186.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats